The efficacy of clozapine in treatment-resistant schizophrenia is limited by significant pharmacokinetic variability due to genetic polymorphisms, drug interactions, and environmental factors, necessitating personalized dosing strategies.
Aims:
This study aimed at developing a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model integrating genetics and clinical factors to guide precision dosing of clozapine.
Methods:
A simulation study was conducted to develop a PBPK/PD model using R (mrgsolve) to simulate clozapine plasma and brain concentrations, multireceptor occupancies, clinical efficacy, and safety risks (agranulocytosis, seizures, cardiotoxicity). The model incorporated multiple genetic profiles (CYP1A2, CYP2D6, and ABCB1), drug interactions (with fluvoxamine and carbamazepine), smoking effects, and ethnic-specific adjustments. Simulations evaluated steady-state outcomes, therapeutic drug monitoring (TDM) protocols, and optimal dosing. Validation used literature datasets, with sensitivity analyses assessing enzyme activity impacts.
Results:
The model demonstrated high predictive accuracy, with simulations revealing substantial variability in clozapine concentrations, primarily driven by CYP1A2 polymorphisms. Model-informed genotype-guided dosing achieved therapeutic levels, markedly improving clinical response and significantly reducing adverse events. Fluvoxamine posed high-risk interactions, particularly in poor metabolizers, while smoking reduced concentrations, requiring dose adjustments. Ethnic-specific dosing addressed population variability, with tailored recommendations for special populations (elderly, pediatric). Sensitivity analyses identified glutathione status as a key determinant in agranulocytosis risk, underscoring the importance of genetic polymorphisms in glutathione S-transferases (GSTT1 and GSTM1) in safety outcomes.
Conclusions:
This PBPK/PD model provides a robust framework for precision clozapine therapy, supporting genotype-guided dosing and TDM to optimize efficacy and safety. The implementation of pharmacogenetic testing could transform clinical practice, offering a framework for optimized resource utilization and risk minimization.
ArranzMJDe LeonJ (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research. Molecular Psychiatry12(8): 707–747.
2.
BertilssonLCarrilloJADahlML, et al. (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology38(5): 471–473.
3.
BousmanCAStevensonJMRamseyLB, et al. (2023) Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics114(1): 51–68.
4.
CarrilloJABenitezJ (2000) Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clinical Pharmacokinetics39(2): 127–153.
5.
CarrilloJAHerraizAGRamosSI, et al. (1998) Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. Journal of Clinical Psychopharmacology18(4): 311–316.
6.
ChenJYangPZhangQ, et al. (2021) Genetic risk of clozapine-induced leukopenia and neutropenia: A genome-wide association study. Translational Psychiatry11(1): 343.
7.
ConsoliGLastellaMCiapparelliA, et al. (2009) ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics10(8): 1267–76.
8.
CouchmanLMorganPESpencerEP, et al. (2010) Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex). Therapeutic Drug Monitoring32(5): 624–627.
9.
Doude Van TroostwijkLJKoopmansRPVermeulenHD, et al. (2003) CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. European Journal of Pharmaceutical Sciences20(4–5): 451–457.
DragovicSBoermaJSVan BergenL, et al. (2010) Role of human glutathione S-transferases in the inactivation of reactive metabolites of clozapine. Chemical Research in Toxicology23(9): 1467–1476.
12.
EiermannBEngelGJohanssonI, et al. (1997) The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. British Journal of Clinical Pharmacology44(5): 439–446.
13.
Erickson-RidoutKKSunDLazarusP (2012) Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)(7)TAA and UGT1A4 L48V polymorphisms. Pharmacogenetics and Genomics22(8): 561–576.
14.
FabrazzoMLa PiaSMonteleoneP, et al. (2002) Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology27(6): 1050–1055.
15.
FlanaganRJDunkL (2008) Haematological toxicity of drugs used in psychiatry. Human Psychopharmacology23(Suppl 1): 27–41.
16.
ForteAPompiliMImbastaroB, et al. (2021) Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. Journal of Psychopharmacology35(9): 1074–1080.
17.
Fricke-GalindoIJung-CookHLLerenaA, et al. (2018) Pharmacogenetics of adverse reactions to antiepileptic drugs. Neurologia (Engl Ed)33(3): 165–176.
18.
GaedigkASimonSDPearceRE, et al. (2008) The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clinical Pharmacology & Therapeutics83(2): 234–242.
19.
GunesADahlML (2008) Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics9(5): 625–637.
20.
HaslemoTEikesethPHTanumL, et al. (2006) The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. European Journal of Clinical Pharmacology62(12): 1049–1053.
21.
HiemkeCBergemannNClementHW, et al. (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry51(1–02): 9–62.
22.
JerlingMLindstromLBondessonU, et al. (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring16(4): 368–374.
23.
KapurSZipurskyRJonesC, et al. (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. The American Journal of Psychiatry157(4): 514–520.
24.
KapurSZipurskyRBRemingtonG (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. The American Journal of Psychiatry156(2): 286–293.
25.
KapurSMamoD. (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuro-Psychopharmacology & Biological Psychiatry27(7): 1081–1090.
26.
LeggeSEHamshereMLRipkeS, et al. (2017) Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular Psychiatry22(10): 1509.
27.
LeggeSEHamshereMLRipkeS, et al. (2018) Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular Psychiatry23(1): 162–163.
28.
LewisSWBarnesTRDaviesL, et al. (2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin32(4): 715–723.
29.
LiebermanJAStroupTSMcEvoyJP, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine353(12): 1209–1223.
30.
LinnetKOlesenOV (1997) Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metabolism and Disposition25(12): 1379–1382.
31.
MachAWnorowskaASiwekM, et al. (2024) The effects of clinical and pharmacological factors on the ratio of clozapine to norclozapine in psychiatric patients. Frontiers in Pharmacology15: 1518739.
32.
McEvoyJPLiebermanJAStroupTS, et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry163(4): 600–610.
33.
MijovicAMacCabeJH (2020) Clozapine-induced agranulocytosis. Annals of Hematology99(11): 2477–2482.
34.
MosselPBartelsALDe DeynPP, et al. (2021) The role of P-glycoprotein at the blood–brain barrier in neurological and psychiatric disease. In: DierckxRAOtteADe VriesEFJ, et al. (eds.) PET and SPECT in Psychiatry. Springer.
35.
NielsenJRogeRSchjerningO, et al. (2012) Geographical and temporal variations in clozapine prescription for schizophrenia. European Neuropsychopharmacology22(11): 818–824.
36.
NordstromALFardeLWieselFA, et al. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biological Psychiatry33(4): 227–235.
37.
OlmosIRicciardiCMatoM, et al. (2025) Optimization of clozapine treatment: Study of variables affecting response in Uruguayan patients with schizophrenia. Journal of Clinical Psychopharmacology45(1): 20–27.
38.
OlssonEEdmanGBertilssonL, et al. (2015) Genetic and clinical factors affecting plasma clozapine concentration. The Primary Care Companion for CNS Disorders17(1): 10.4088/PCC.14m01704.
39.
OzdemirVKalowWPosnerP, et al. (2001) CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. Journal of Clinical Psychopharmacology21(4): 398–407.
40.
PartanenJJHappolaPKampeA, et al. (2024) High burden of ileus and pneumonia in clozapine-treated individuals with schizophrenia: A Finnish 25-year follow-up register study. American Journal of Psychiatry181(10): 879–892.
PolasekTMShakibSRostami-HodjeganA (2018) Precision dosing in clinical medicine: present and future. Expert Review of Clinical Pharmacology11(8): 743–746.
43.
RafizadehRSoochARisiA, et al. (2024) Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder. Journal of Psychopharmacology38(6): 526–531.
44.
R Core Team (2023). R: A language and environment for statistical computing (Version 4.2.3) [Computer software]. Vienna, Austria: R Foundation for Statistical Computing. Available at: https://www.R-project.org/
45.
Rostami-HodjeganAAminAMSpencerEP, et al. (2004) Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. Journal of Clinical Psychopharmacology24(1): 70–78.
46.
Rostami-HodjeganATuckerGT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews Drug Discovery6(2): 140–148.
47.
ShebleyMSandhuPEmami RiedmaierA, et al. (2018) Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: A consortium perspective. Clinical Pharmacology & Therapeutics104(1): 88–110.
48.
SpinaEDe LeonJ (2007) Metabolic drug interactions with newer antipsychotics: A comparative review. Basic & Clinical Pharmacology & Toxicology100(1): 4–22.
49.
SullivanPFAgrawalABulikCM, et al. (2018) Psychiatric genomics: An update and an agenda. American Journal of Psychiatry175(1): 15–27.
50.
TugnaitMHawesEMMcKayG, et al. (1997) N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metabolism and Disposition25(4): 524–527.
51.
UrichukLPriorTIDursunS, et al. (2008) Metabolism of atypical antipsychotics: Involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Current Drug Metabolism9(5): 410–418.
52.
WetzelHAnghelescuISzegediA, et al. (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. Journal of Clinical Psychopharmacology18(1): 2–9.
53.
WillcocksIRLeggeSENalmpantiM, et al. (2021) Clozapine metabolism is associated with absolute neutrophil count in individuals with treatment-resistant schizophrenia. Frontiers in Pharmacology12: 658734.
54.
WilliamsAMParkSH (2015) Seizure associated with clozapine: Incidence, etiology, and management. CNS Drugs29(2): 101–111.
55.
WongJDelvaN (2007) Clozapine-induced seizures: recognition and treatment. The Canadian Journal of Psychiatry52(7): 457–463.
